Safety Profile and Adverse Event Management for Futibatinib, an Irreversible FGFR1-4 Inhibitor: Pooled Safety analysis of 469 patients.

Funda Meric-Bernstam Antoine Hollebecque Junji Furuse Do Youn Oh John A Bridgewater Masashi Shimura Bailey Anderson Nanae Hangai Volker Wacheck Lipika Goyal

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Futibatinib showed a consistent and manageable safety profile across patients with various tumor types. AECIs were mostly reversible with appropriate clinical management.

Keyphrases

emergency department
open label
phase iii
drug induced